Findings observed in laboratory investigations should not be interpreted as evidence of therapeutic efficacy, clinical utility, or approved medical applications
This makes it a candidate for oral or subcutaneous delivery depending on the goal
GLP-1 (Semaglutide) Program GLP-1 Weight Management Program Skinny Me Med is now offering an exclusive Weight Loss Program featuring weekly GLP-1 analogue injections, designed to support effective and sustainable weight management
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
However, certain symptoms may be signs of a more serious complication